Product Name |
CDK9 |
CDK1 |
CDK2 |
CDK3 |
CDK4 |
CDK5 |
CDK6 |
CDK7 |
CDK8 |
CDK12 |
CDK13 |
CDK14 |
CDK16 |
CDK19 |
CDK9 Selectivity |
Purity |
KB-0742 dihydrochloride |
CDK9/cyclinT1, IC50: 6 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.63% |
AZD4573 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.90% |
NVP-2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
≥98.0% |
(+)-BAY-1251152 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.66% |
LDC000067 |
CDK9- Cyclin T1, IC50: 44 nM
|
cdk1-cyclin B1, IC50: 5513 nM
|
cdk2-cyclin A, IC50: 2441 nM
|
|
cdk4-cyclin D1, IC50: 9242 nM
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
98.58% |
PHA-767491 hydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.91% |
Atuveciclib |
CDK9/CycT1, IC50: 13 nM
CDK9/CycT1(h), IC50: 6 nM
|
CDK1/CycB(h), IC50: 1100 nM
|
CDK2/CycE(h), IC50: 1000 nM
|
CDK3/CycE(h), IC50: 890 nM
|
|
CDK5/p35(h), IC50: 1600 nM
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.20% |
CDK9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
95.48% |
CDK-IN-2 |
CDK9/cyclinT1, IC50: 8 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
98.82% |
PROTAC CDK9 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
98.34% |
CDK12-IN-E9 |
CDK9/cyclinT1, IC50: 23.9 nM
|
|
cdk2/cyclin A, IC50: 932 nM
|
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: 1210 nM
|
|
|
|
|
|
|
Selective Inhibitor
|
99.20% |
MC180295 |
CDK9- Cyclin T1, IC50: 5 nM
|
CDK1-Cyclin B, IC50: 138 nM
|
cdk2-cyclin A, IC50: 233 nM
cdk2-cyclin E, IC50: 367 nM
|
CDK3-Cyclin E, IC50: 399 nM
|
CDK4-Cyclin D, IC50: 112 nM
|
cdk5-p35, IC50: 159 nM
cdk5-p25, IC50: 186 nM
|
cdk6-cyclin D3, IC50: 712 nM
|
CDK7-CycH/MAT1, IC50: 555 nM
|
|
|
|
|
|
|
Selective Inhibitor
|
98.47% |
CDK9-IN-7 |
CDK9/cyclinT1, IC50: 11 nM
|
|
|
|
CDK4/cyclin D, IC50: 148 nM
|
|
CDK6/cyclinD, IC50: 145 nM
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.81% |
CDK9-IN-8 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
99.06% |
JSH-150 |
CDK9/cyclinT1, IC50: 1 nM
|
Cdk1/cyclin B, IC50: 1.34 μM
|
cdk2/cyclin A, IC50: 2.86 μM
|
|
|
|
|
CDK7/Cyclin H/MNAT1, IC50: 1.72 μM
|
|
|
|
CDK14/Cyclin Y, IC50: 1.68 μM
|
CDK16/Cyclin Y, IC50: 292 nM
|
|
Selective Inhibitor
|
98.36% |
CAN508 |
CDK9/cyclinT1, IC50: 0.35 μM
|
Cdk1/cyclin B, IC50: 44 μM
|
CDK2/cyclinE, IC50: 20 μM
cdk2/cyclin A, IC50: 69 μM
|
|
Cdk4/cyclin D1, IC50: 13.5 μM
|
|
|
CDK7/cyclin H, IC50: 26 μM
|
|
|
|
|
|
|
Selective Inhibitor
|
|
FIT-039 |
CDK9/cyclinT1, IC50: 5.8 μM
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
≥98.0% |
PHA-767491 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
|
CDK9-IN-9 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
|
PROTAC CDK9 degrader-2 |
CDK9, IC50: 17 μM (MCF-7 cells)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
|
CDK6/9-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
|
CDK9-IN-11 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
|
CDK9-IN-10 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selective Inhibitor
|
|
Abemaciclib |
CDK9/cyclinT1, IC50: 57 nM
|
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk4/cyclin D1, IC50: 2 nM
|
CDK5/p35, IC50: 287 nM
Cdk5/p25, IC50: 355 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.69% |
Dinaciclib |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.36% |
Abemaciclib methanesulfonate |
CDK9/cyclinT1, IC50: 57 nM
|
CDK1/cyclinB1, IC50: 1627 nM
|
CDK2/cyclinE, IC50: 504 nM
|
|
Cdk4/cyclin D1, IC50: 2 nM
|
Cdk5/p25, IC50: 355 nM
CDK5/p35, IC50: 287 nM
|
CDK6/cyclinD1, IC50: 10 nM
|
CDK7/Mat1/cyclinH1, IC50: 3910 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
≥98.0% |
THZ531 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.86% |
CYC065 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.78% |
SNS-032 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.50% |
AZD-5438 |
cdk9-cyclin T, IC50: 20 nM
|
cdk1-cyclin B1, IC50: 16 nM
|
cdk2-cyclin E, IC50: 6 nM
cdk2-cyclin A, IC50: 45 nM
|
|
cdk4-cyclin D1, IC50: 449 nM
|
|
cdk6-cyclin D3, IC50: 21 nM
|
cdk7-cyclin H, IC50: 821 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.37% |
AT7519 |
CDK9/Cyclin T, IC50: 10 nM
|
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.40% |
Samuraciclib hydrochloride |
|
|
cdk2/cyclin A, IC50: 578 nM
|
|
|
CDK5/p35NCK, IC50: 9.4 μM
|
|
CDK7/cyclin H, IC50: 41 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.98% |
CGP60474 |
|
CDK1-Cyclin B, IC50: 26 nM
|
CDK2/cyclinE, IC50: 3 nM
cdk2/cyclin A, IC50: 4 nM
|
|
CDK4/cyclin D, IC50: 216 nM
|
|
|
CDK7/cyclin H, IC50: 200 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
98.70% |
YKL-5-124 TFA |
|
|
|
|
|
|
|
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
|
THZ2 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥95.0% |
Roniciclib |
CDK9/cyclinT1, IC50: 5 nM
|
Cdk1/cyclin B, IC50: 7 nM
|
|
|
CDK4/cyclin D, IC50: 11 nM
|
|
|
CDK7/Cyclin H/MAT1, IC50: 25 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
98.89% |
SEL120-34A monohydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
Pan Inhibitor
|
99.98% |
PHA-793887 |
CDK9/cyclinT1, IC50: 138 nM
|
Cdk1/cyclin B, IC50: 60 nM
|
cdk2/cyclin A, IC50: 8 nM
CDK2/cyclinE, IC50: 8 nM
|
|
Cdk4/cyclin D1, IC50: 62 nM
|
|
|
CDK7/cyclin H, IC50: 10 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.25% |
(R)-CR8 trihydrochloride |
CDK9/Cyclin T, IC50: 0.18 μM
|
CDK1/cyclinB1, IC50: 0.09 μM
|
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
|
|
|
|
|
CDK7/cyclin H, IC50: 1.1 μM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.02% |
LY2857785 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.88% |
BS-181 |
|
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
|
|
|
|
|
Pan Inhibitor
|
98.10% |
Riviciclib hydrochloride |
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.500 μM
|
|
cdk4-cyclin D1, IC50: 0.063 μM
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
|
|
|
|
|
|
Pan
|
98.33% |
AT7519 Hydrochloride |
CDK9/Cyclin T, IC50: 10 nM
|
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.99% |
Atuveciclib Racemate |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥98.0% |
CDKI-73 |
CDK9, IC50: 5.78 nM
CDK9, Ki: 4 nM
|
CDK1, IC50: 8.17 nM
CDK1, Ki: 4 nM
|
CDK2, IC50: 3.27 nM
CDK2, Ki: 3 nM
|
|
|
|
|
CDK7, IC50: 134.26 nM
CDK7, Ki: 91 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.58% |
(R)-CR8 |
CDK9/Cyclin T, IC50: 0.18 μM
|
Cdk1/cyclin B, IC50: 0.09 μM
|
cdk2/cyclin A, IC50: 0.072 μM
CDK2/cyclinE, IC50: 0.041 μM
|
|
|
|
|
CDK7/cyclin H, IC50: 1.1 μM
|
|
|
|
|
|
|
Pan Inhibitor
|
≥98.0% |
BS-181 hydrochloride |
|
|
CDK2/Cyc E, IC50: 0.88 μM
|
|
|
|
|
CDK7/CycH/MAT1, IC50: 0.021 μM
|
|
|
|
|
|
|
Pan Inhibitor
|
≥99.0% |
Voruciclib hydrochloride |
CDK9/CycT1, Ki: 1.68 nM
CDK9/cyc T2, Ki: 0.626 nM
|
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
98.20% |
Lerociclib dihydrochloride |
CDK9/Cyclin T, IC50: 28 nM
|
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
CDK5/p35, IC50: 832 nM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
|
|
|
|
|
|
Pan Inhibitor
|
98.45% |
SEL120-34A HCl |
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
Pan Inhibitor
|
99.98% |
Voruciclib |
CDK9/cyc T2, Ki: 0.626 nM
CDK9/CycT1, Ki: 1.68 nM
|
CDK1/cycB, Ki: 5.4 nM
CDK1/cyc A, Ki: 9.1 nM
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
99.52% |
NVP-LCQ195 |
CDK9/cyclinT1, IC50: 15 nM
|
Cdk1/cyclin B, IC50: 2 nM
|
cdk2/cyclin A, IC50: 2 nM
CDK2/cyclinE, IC50: 5 nM
|
CDK3/Cyclin E, IC50: 42 nM
|
|
Cdk5/p25, IC50: 1 nM
CDK5/p35, IC50: 1 nM
|
cdk6/cyclin D3, IC50: 187 nM
|
CDK7/Cyclin H/MAT1, IC50: 3564 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
99.80% |
PROTAC CDK2/9 Degrader-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
SEL120-34A |
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 10.4 nM
|
Pan Inhibitor
|
|
AT7519 trifluoroacetate |
CDK9/Cyclin T, IC50: 10 nM
|
Cdk1/cyclin B, IC50: 210 nM
|
cdk2/cyclin A, IC50: 47 nM
|
|
Cdk4/cyclin D1, IC50: 100 nM
|
|
cdk6/cyclin D3, IC50: 170 nM
|
CDK7/Cyclin H/MAT1, IC50: 2400 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
98.16% |
CDK8/19-IN-1 |
|
|
|
|
|
|
|
|
|
|
|
|
|
CDK19/CycC, IC50: 0.99 nM
|
Pan Inhibitor
|
|
IIIM-290 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Riviciclib |
CDK9- Cyclin T1, IC50: 0.020 μM
CDK9-cyclin H, IC50: 2.900 μM
|
CDK1-Cyclin B, IC50: 0.079 μM
|
cdk2-cyclin A, IC50: 0.224 μM
cdk2-cyclin E, IC50: 2.540 μM
|
|
cdk4-cyclin D1, IC50: 0.063 μM
|
|
cdk6-cyclin D3, IC50: 0.396 μM
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
TL12-186 |
CDK9/cyclinT1, IC50: 55 nM
|
|
cdk2/cyclin A, IC50: 73 nM
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Lerociclib |
CDK9/Cyclin T, IC50: 28 nM
|
CDK1/cyclinB1, IC50: 2.4 μM
|
cdk2/cyclin A, IC50: 1.5 μM
CDK2/cyclinE, IC50: 3.6 μM
|
|
Cdk4/cyclin D1, IC50: 1 nM
|
CDK5/p35, IC50: 0.832 μM
Cdk5/p25, IC50: 1.2 μM
|
cdk6/cyclin D3, IC50: 2 nM
|
CDK7/Cyclin H/MAT1, IC50: 2.4 μM
|
|
|
|
|
|
|
Pan Inhibitor
|
|
CDK7-IN-3 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
BS-181 dihydrochloride |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
|
Bohemine |
CDK9/cyclinT1, IC50: 2.7 μM
|
|
CDK2/cyclinE, IC50: 4.6 μM
cdk2/cyclin A, IC50: 83 μM
|
|
|
|
|
|
|
|
|
|
|
|
Pan Inhibitor
|
≥98.0% |
YKL-5-124 |
|
|
|
|
|
|
|
CDK7, IC50: 53.5 nM
CDK7/Mat1/CycH, IC50: 9.7 nM
|
|
|
|
|
|
|
Pan Inhibitor
|
|
(-)-BAY-1251152 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Inhibitor
|
99.82% |
FN-1501-propionic acid |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|